Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Open to people ages 18 years and up

• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
• Have pathologically confirmed World Health Organization (WHO) grading system employed for tumor grading) high-risk NMIBC unresponsive to prior BCG therapy defined as:

Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy

• Received prior adequate BCG therapy as defined as at least one of the following ("5+2" minimum exposure):
• At least five of six doses of an initial induction course (adequate induction) plus at least two of three doses of maintenance therapy, OR
• At least five of six doses of an initial induction course (adequate induction) plus at least two of six doses of a second induction course.
• Ineligible for radical cystectomy or refusal of radical cystectomy
• Adequate organ function

• Muscle invasive (T2 or higher stage) or locally advanced (T3/T4, any N) or metastatic bladder cancer
• Has known upper tract or prostatic urethra malignancy
• Has systemic anti-cancer therapy, including investigational agents, within 4 weeks of Baseline
• Immuno-deficient due to chronic steroid or other immunosuppressant use, HIV, or prior organ transplant
• Prior treatment with adenovirus-based cancer therapy
• Clinically significant or active cardiac disease
• Active autoimmune disease